Abstract
Conventional Nuclear Medicine examinations are still valuable in pediatric endocrine system diseases and contribute to clinical evaluation. In this review, information will be given about thyroid and parathyroid diseases and adrenal gland imaging, which are frequently seen in the pediatric age group, and in which Nuclear Medicine examinations are actively used in diseases involving the endocrine system. In addition to the clinical investigation of the congenital anomalies of the related organs and their relationship with syndromes, malignant processes are also evaluated with conventional Nuclear Medicine methods, and their effective role in the treatment of malignant processes continues by pioneering theranostic applications. Since computed tomography and magnetic resonance imaging are more prominent in the imaging of pituitary gland, hypothalamus, and pancreas diseases, they are not included in this review.
Keywords: Pediatric, endocrine diseases, scintigraphy, thyroid, parathyroid, adrenal gland, PET/CT
References
Livett T, LaFranchi S. Imaging in congenital hypothyroidism. Curr Opin Pediatr. 2019;31:555-561.
Li WI, Chan TK, Ng KK, Kung BT. Predictive value of technetium-99m sodium pertechnetate thyroid scintigraphy in determining the permanence of congenital hypothyroidism. J Clin Imaging Sci. 2025;15:3.
Léger J, Oliver I, Rodrigue D, Lambert AS, Coutant R. Graves’ disease in children. Ann Endocrinol. 2018;79:647-655.
Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on pediatric thyroid cancer. Thyroid. 2015;25:716-759.
Lebbink CA, Links TP, Czarniecka A, et al. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J. 2022;11:e220146.
Parisi MT, Eslamy H, Mankoff D. Management of differentiated thyroid cancer in children: focus on the American Thyroid Association Pediatric Guidelines. Semin Nucl Med. 2016;46:147-164.
Niedziela M, Breborowicz D, Trejster E. Hot nodules in children and adolescents in western Poland from 1996-2000: Clinical analysis of 31 patients. J Pediatr Endocrinol Metab. 2002;15:823-830.
Freudenberg LS, Jentzen W, Marlowe RJ. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with dif- ferentiated thyroid cancer. Exp Clin Endocrinol Diabetes. 2007;115:690-693.
Eschmann SM, Reischl G, Bilger K. Evaluation of dosimetry of radio- iodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760-767.
Bal CS, Garg A, Chopra S. Prognostic factors in pediatric differentiated thyroid cancer patients with pulmonary metastases. J Pediatr Endocrinol Metab. 2015;8:745-751.
Biko J, Reiners C, Kreissl MC. Favourable course of disease after in- complete remission on I-131 therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl Med Mol Imaging. 2011;38:651-655.
Brink JS, Heerden JA, McIver B. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery. 2000;128:881-887.
Sisson JC, Jamadar DA, Kazerooni EA. Iodine-l3l treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer. 1996;78:2184-2192.
Barmpari ME, Savvidis C, Dede AD, et al. Adrenal malignant melanoma masquerading as a pheochromocytoma in a patient with a history of a multifocal papillary and medullary thyroid carcinoma. Hormones. 2016;15:283-290.
Yang JH, Camacho CP, Lindsey SC, et al. The combined use of calcitonin doubling time and 18F-FDG PET/CT improves prognostic values in medullary thyroid carcinoma: the clinical utility of 18F-FDG PET/CT. Endocr Pract. 2017;23:942-948.
Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018;91:20180103.
Khalatbari H, Cheeney SHE, Manning SC, Parisi MT. Pediatric hyperparathyroidism: review and imaging update. Pediatr Radiol. 2021;51:1106-1120.
He Y, Luo Y, Jin S, et al. Can we skip technetium-99 m sestamibi scintigraphy in pediatric primary hyperparathyroidism patients with positive neck ultrasound results? Pediatr Radiol. 2023;53:2253-2259.
Miyakoshi M, Kamoi K, Takano T, et al. Multiple brown tumors in primary hyperparathyroidism caused by an adenoma mimicking metastatic bone disease with false positive results on computed tomography and Tc-99m sestamibi imaging: MR findings. Endocr J. 2007;54:205-210.
Gonnelli S, Briot K, Cormier C, Teboul S, Roux C, Koumakis E. Multiple brown tumors: a bone complication due to long-term untreated pseudohypoparathyroidism. Osteoporos Int. 2024;35:195-199.
Gedik GK, Ata O, Karabagli P, Sari O. Differential diagnosis between secondary and tertiary hyperparathyroidism in a case of a giant-cell and brown tumor containing mass. Findings by (99m)Tc-MDP, (18)F-FDG PET/CT and (99m)Tc-MIBI scans. Hell J Nucl Med. 2014;17:214-217.
Prabhu M, Kumari G, Damle NA, et al. Assessment of the role of early dynamic PET/CT with 18F-fluorocholine in detection of parathyroid lesions in patients with primary hyperparathyroidism. Nucl Med Commun. 2018;39:1190-1196.
Martínez Sánchez H, Moreno Macián F, León Cariñena S, de Mingo Alemany C, Blasco González L, Sánchez Vañó R. Use of [18F]fluorocholine PET/CT in the detection of primary hyperparathyroidism in paediatrics: a case report. J Pediatr Endocrinol Metab. 2024;37:580-584.
Bholah R, Bunchman TE. Review of pediatric pheochromocytoma and paraganglioma. Front Pediatr. 2017;5.
Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68 Ga-DOTA–conjugated somatostatin receptor–targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med. 2019;60:369-376.
Zhang X, Wakabayashi H, Hiromasa T, Kayano D, Kinuya S. Recent advances in radiopharmaceutical theranostics of pheochromocytoma and paraganglioma. Semin Nucl Med. 2023;53:503-516.
Zi J, Ma C, Xu C, Bai Y. A pediatric malignant paraganglioma and brief review of the literature. Hell J Nucl Med. 2016;19:281-284.
Theerakulpisut D, Raruenrom Y, Wongsurawat N, Somboonporn C. Value of SPECT/CT in diagnostic I-131 MIBG scintigraphy in patients with neuroblastoma. Nucl Med Mol Imaging. 2018;52:350-358.
Willegaignon J, Crema KP, Oliveira NC, et al. Pediatric 131I-MIBG therapy for neuroblastoma: whole-body 131I-MIBG clearance, radiation doses to patients, family caregivers, medical staff, and radiation safety measures. Clin Nucl Med. 2018;43:572-578.
Ladenstein R, Lambert B, Pötschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292-305.
Liu B, Servaes S, Zhuang H. SPECT/CT mibg imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232-238.
Sokol EA, Engelmann R, Kang W, et al. Computer‐assisted curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018;65:e27417.
Genolla J, Rodriguez T, Minguez P, Lopez-Almaraz R, Llorens V, Echebarria A. Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2019;46:1567-1575.
Anongpornjossakul Y, Sriwatcharin W, Thamnirat K, et al. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma: Nucl Med Commun. 2020;41:336-343.
Pauwels E, Celen S, Vandamme M, et al. Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter–expressing tumour. Eur J Nucl Med Mol Imaging. 2021;48:313-315.
Borgwardt L, Brok J, Andersen KF, et al. Performing [ 18 F]MFBG long–axial-field-of-view PET/CT without sedation or general anesthesia for imaging of children with neuroblastoma. J Nucl Med. 2024;jnumed.123.267256.
Samim A, Blom T, Poot AJ, et al. [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1146-1157.
Maaz AUR, O’Doherty J, Djekidel M. 68 Ga-DOTATATE PET/CT for neuroblastoma staging: utility for clinical use. J Nucl Med Technol. 2021;49:265-268.
Koo SX. Selective use of peptide receptor radionuclide therapy following comparative imaging of Ga-68 DOTATATE PET/CT against I-131 MIBG scintigraphy in a small Asian cohort of Adult Neuroblastoma. Med J Malaysia. 2021;76.
Telli T, Lay Ergün E, Volkan Salanci B, Özgen Kiratli P. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45:326-329.
Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020;41:1169-1177.
Mittal B, Agrawal K, Kumar R, Bhattacharya A, Mittal BR. Ga-68 DOTATATE positron emission tomography/computer tomography in initial staging and therapy response evaluation in a rare case of primary neuroblastoma in neck. Indian J Nucl Med. 2014;29:175.
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of gallium-68 DOTATOC and gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55:389-398.
Shukla J, Sodhi K, Bansal D, et al. 68 Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors. Indian J Nucl Med. 2014;29:13.
Bodei L, Ambrosini V, Herrmann K, Modlin I. Current concepts in 68 Ga-DOTATATE imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies. J Nucl Med. 2017;58:1718-1726.
Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy with 177 Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. Am J Roentgenol. 2019;213:309-317.
Wagner MW, Bilbily A, Beheshti M, Shammas A, Vali R. Artificial intelligence and radiomics in pediatric molecular imaging. Methods. 2021;188:37-43.
Hirata K, Manabe O, Magota K, Furuya S, Shiga T, Kudo K. A preliminary study to use SUVmax of FDG PET-CT as an identifier of lesion for artificial intelligence. Front Med. 2021;8:647562.
